STRO Key Statistics, Chart & Performance
The current stock price of STRO is 11.49 USD. In the past month the price increased by 25%. In the past year, price decreased by -43.12%.
STRO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.34 | 406.46B | ||
| AMGN | AMGEN INC | 15.22 | 179.28B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 154.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.66 | 117.45B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.44 | 82.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.47 | 52.92B | ||
| INSM | INSMED INC | N/A | 37.94B | ||
| NTRA | NATERA INC | N/A | 32.26B | ||
| BIIB | BIOGEN INC | 10.58 | 25.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.22 | 21.84B | ||
| INCY | INCYTE CORP | 15.59 | 19.65B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About STRO
Company Profile
Sutro Biopharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in South San Francisco, California and currently employs 178 full-time employees. The company went IPO on 2018-09-27. Sutro Biopharma, Inc. is an oncology company engaged in developing site-specific and novel-format antibody drug conjugates (ADCs), enabled by its proprietary integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. The company designs and develops therapeutics using the relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, and dual conjugate ADCs. Enabled through its XpressCF and XpressCF+ platforms, it has entered multi-target, product-focused collaborations with pharmaceutical and biotechnology companies in the field of oncology, with its ongoing relationships that include licensing to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. STRO-003 is developed for the treatment of solid tumors. Its XpressCF and XpressCF platforms supports Vaxcyte, focused on discovery and development of vaccines for the treatment and prophylaxis of infectious disease.
Company Info
SUTRO BIOPHARMA INC
111 Oyster Point Blvd.
South San Francisco CALIFORNIA 94080 US
CEO: William J. Newell
Employees: 178
Phone: 16503928412
SUTRO BIOPHARMA INC / STRO FAQ
What does SUTRO BIOPHARMA INC do?
Sutro Biopharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in South San Francisco, California and currently employs 178 full-time employees. The company went IPO on 2018-09-27. Sutro Biopharma, Inc. is an oncology company engaged in developing site-specific and novel-format antibody drug conjugates (ADCs), enabled by its proprietary integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. The company designs and develops therapeutics using the relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, and dual conjugate ADCs. Enabled through its XpressCF and XpressCF+ platforms, it has entered multi-target, product-focused collaborations with pharmaceutical and biotechnology companies in the field of oncology, with its ongoing relationships that include licensing to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. STRO-003 is developed for the treatment of solid tumors. Its XpressCF and XpressCF platforms supports Vaxcyte, focused on discovery and development of vaccines for the treatment and prophylaxis of infectious disease.
What is the stock price of SUTRO BIOPHARMA INC today?
The current stock price of STRO is 11.49 USD. The price increased by 6.88% in the last trading session.
What is the dividend status of SUTRO BIOPHARMA INC?
STRO does not pay a dividend.
What is the ChartMill technical and fundamental rating of STRO stock?
STRO has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What do analysts say about SUTRO BIOPHARMA INC (STRO) stock?
16 analysts have analysed STRO and the average price target is 35.99 USD. This implies a price increase of 213.24% is expected in the next year compared to the current price of 11.49.
Would investing in SUTRO BIOPHARMA INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on STRO.
Can you provide the growth outlook for SUTRO BIOPHARMA INC?
The Revenue of SUTRO BIOPHARMA INC (STRO) is expected to grow by 68.12% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
STRO Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to STRO. When comparing the yearly performance of all stocks, STRO is a bad performer in the overall market: 78.34% of all stocks are doing better.
STRO Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to STRO. STRO may be in some trouble as it scores bad on both profitability and health.
STRO Financial Highlights
Over the last trailing twelve months STRO reported a non-GAAP Earnings per Share(EPS) of -9.9. The EPS decreased by -514.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -103.18% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
STRO Forecast & Estimates
16 analysts have analysed STRO and the average price target is 35.99 USD. This implies a price increase of 213.24% is expected in the next year compared to the current price of 11.49.
For the next year, analysts expect an EPS growth of -639.88% and a revenue growth 68.12% for STRO